EUVIMEDEUVIMED entdecken
Open Access

EXONERATE-TRaCE: A Liquid Biopsy for Tracking Response to Anti–Epidermal Growth Factor Receptor–Based Therapy in Metastatic Colorectal Cancer

Toshiaki Takahashi iD, Alessandro Mannucci iD, Kunitoshi Shigeyasu iD, Scott Kopetz iD, Marwan Fakih iD, Joan Maurel iD, Toshiyoshi Fujiwara iD, Ajay Goel iD

JCO Precision Oncology · 2026-05 · 10 (5)

DOI: 10.1200/po-25-01229 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2026-05. Verfasst von Toshiaki Takahashi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope, Biomedical Research Center, Monrovia, …. Hauptthemen laut MEDLINE: Colorectal Neoplasms. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The EXOsome and cell-free microRNAs (miRNAs) of anti–epidermal growth factor receptor (EGFR) Resistance (EXONERATE) study previously developed and validated a liquid biopsy to predict the efficacy of first-line anti-EGFR therapy in metastatic colorectal cancer (mCRC) from treatment-naïve blood samples. This study evaluates the performance of the EXONERATE assay during therapy as a tool for monitoring the emergence of anti-EGFR resistance before it becomes clinically or radiologically apparent. METHODS Retrospective, single-center, longitudinal, REMARK-compliant biomarker study assessing the ability of a liquid biopsy to predict response to anti-EGFR monoclonal antibodies and to track resistance development longitudinally. Fifty-two patients with RAS wild-type mCRC provided 142 plasma samples during administration of first-line anti-EGFR–based therapy. RESULTS Baseline EXONERATE scores predicted response with 83.3% specificity and 77.3% sensitivity (area under the receiver operating characteristic curve [AUROC] = 89.4%). Longitudinal analyses demonstrated that biomarker changes closely tracked tumor burden and anticipated clinical and radiological progression, outperforming conventional tumor markers CEA and CA19-9. Stepwise optimization produced a reduced panel (four cell-free-miRNAs and five exo-miRNAs), EXONERATE-Tracking Response and Clinical Evolution (TRaCE), which retained high predictive accuracy (AUROC = 94.4%) while enabling more practical, repeated monitoring. EXONERATE-TRaCE values increased during the 3 months preceding the first clinical or radiological evidence of progression and reliably detected early progression in both left- and right-sided tumors, including patients with lung metastases, and identified resistance up to 3 months before radiological confirmation. CONCLUSION EXONERATE-TRaCE extends the predictive utility of the original EXONERATE assay into a practical monitoring tool. This liquid biopsy detects emerging anti-EGFR resistance earlier than conventional markers and may inform treatment monitoring and support timely clinical decision making in mCRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsHumansLiquid BiopsyRetrospective StudiesErbB ReceptorsFemaleBiomarkers, TumorMaleDrug Resistance, NeoplasmMiddle AgedAgedNeoplasm MetastasisLongitudinal Studies

Substanzen

ErbB ReceptorsBiomarkers, TumorEGFR protein, human

Autor:innen und Institutionen

  • Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope, Biomedical Research Center, Monrovia, CA.
  • Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
  • Gastroenterology and Gastrointestinal Endoscopy Unit, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy.
  • The University of Texas MD Anderson Cancer Center, Houston, TX.
  • City of Hope Medical Center, Duarte, CA.
  • Department of Medical Oncology, Hospital Clinic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, University of Barcelona, Barcelona, Spain.

ORCID-Profile: Toshiaki Takahashi, Alessandro Mannucci, Kunitoshi Shigeyasu, Scott Kopetz, Marwan Fakih, Joan Maurel, Toshiyoshi Fujiwara, Ajay Goel

Förderung

  • NCI NIH HHS

Zitieren

APA

Takahashi, T., Mannucci, A., Shigeyasu, K., Kopetz, S., Fakih, M., Maurel, J., Fujiwara, T., & Goel, A. (2026). EXONERATE-TRaCE: A Liquid Biopsy for Tracking Response to Anti–Epidermal Growth Factor Receptor–Based Therapy in Metastatic Colorectal Cancer. JCO Precision Oncology, 10(5). https://doi.org/10.1200/po-25-01229

Vancouver

Takahashi T, Mannucci A, Shigeyasu K, Kopetz S, Fakih M, Maurel J, et al. EXONERATE-TRaCE: A Liquid Biopsy for Tracking Response to Anti–Epidermal Growth Factor Receptor–Based Therapy in Metastatic Colorectal Cancer. JCO Precision Oncology. 2026;10(5). doi:10.1200/po-25-01229

BibTeX
@article{Takahashi2026,
  author = {Takahashi, Toshiaki and Mannucci, Alessandro and Shigeyasu, Kunitoshi and Kopetz, Scott and Fakih, Marwan and Maurel, Joan and Fujiwara, Toshiyoshi and Goel, Ajay},
  title = {EXONERATE-TRaCE: A Liquid Biopsy for Tracking Response to Anti–Epidermal Growth Factor Receptor–Based Therapy in Metastatic Colorectal Cancer},
  journal = {JCO Precision Oncology},
  year = {2026},
  volume = {10},
  number = {5},
  doi = {10.1200/po-25-01229}
}
Kostenlos starten →